FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
|
Thread Tools | Display Modes |
10-19-2009, 06:38 PM | #1 | ||
|
|||
In Remembrance
|
Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
OR Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease open label see: http://clinicaltrials.gov/ct2/show/N...urturin&rank=1 Curently recruiting at : United States, New York Mount Sinai Medical Center United States, Georgia Emory University Not yet recruiting Atlanta, Georgia, United States Principal Investigator: Nicholas M. Boulis, M.D. Sub-Investigator: Mahlon R. DeLong, M.D There aren't enough slots for all of the sham surgery participants but the first up is a forum member who got sham surgery first time around.
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
CERE-120 Neuturin | Parkinson's Disease | |||
CERE-120 /May2009/ Clinical Data from Phase 2 Trial of CERE-120 for PD | Parkinson's Disease Clinical Trials | |||
Cere 120 - The Story | Parkinson's Disease Clinical Trials | |||
Cere-120 | Parkinson's Disease | |||
Ceregene is updating Cere 120 | Parkinson's Disease Clinical Trials |